Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Otherwise healthy participants
Positive test for influenza A infection
No more than 72 hours elapsed between onset of influenza-like illness and start of study drug
Presence of at least one moderate or severe constitutional symptom such as headache, myalgia, fever, chills, fatigue, anorexia, or nausea PLUS one moderate or severe respiratory symptom such as cough, sore throat, or rhinorrhea
For women of childbearing potential: negative pregnancy test and agreement to use acceptable contraceptive methods for at least 120 days after study drug administration
For men: agreement to use acceptable contraceptive methods for at least 30 days after study drug administration
You may not be if
Creatinine clearance less than or equal to (\</=) 80 milliliters per minute (mL/min)
Any significant medical conditions or laboratory abnormalities
Clinical signs and symptoms consistent with otitis, bronchitis, sinusitis, or pneumonia or active bacterial infection
Use of antiviral therapy in the period from onset of influenza-like illness and prior to enrollment
Pregnancy at Screening or is currently pregnant or breastfeeding
Investigational therapy within 30 days or 5 half-lives prior to start of study drug, whichever is greater
Prior anti-influenza monoclonal antibody use
Receipt of a nasal influenza A vaccine within 14 days prior to Screening
Positive test for influenza B or influenza A+B within 2 weeks prior to study drug
History of significant tobacco use or drug/alcohol abuse
Chronic use of oral or inhaled corticosteroids within 30 days prior to Screening
Autoimmune disease, known immunodeficiency of any cause, or use of immunosuppressive medications
History of any chronic respiratory condition
Human immunodeficiency virus (HIV) with cluster of differentiation (CD) 4 count \</= 200 cells per milliliter (cells/mL) in the past 12 months
Serious infection requiring oral or IV antibiotics within 14 days prior to Screening
